Rayno Biopharmaceuticals Portfolio: Performance 9/30/17 YTD
Objective: Develop a medium term biotech portfolio that assumes a bull market for 2017 with positions in two core ETFs, large cap dividend plays and speculative picks in breakthrough technologies: CAR-T and pharmacogenomics. Most positions were added in 2016 but XBI was added in January 2017.
Top winners:
BLUE up 122.6%
XBI up 46.26%
ABBV up 41.9%
Company | Ticker | Date | Price | Price | Perf | 9/30 | Perf % | |
Started | 4/25 | % | P | YTD | ||||
Abbvie | ABBV | 2/3/16 | 56.5 | 65.45 | 16 | 88.86 | 41.9 | |
Amgen | AMGN | 9/12/16 | 172 | 165 | -4 | 186.45 | 27.52 | |
Biogen | BIIB | 2/13/17 | 275 | 286.5 | 4.5 | 313.12 | 10.42 | |
bluebird bio | BLUE | 2/3/16 | 43.75 | 88.1 | 103 | 137.35 | 122.6 | |
Bristol Myers | BMY | 2/16/16 | 61 | 54.2 | -7.7 | 63.74 | 9.07 | |
Foundation Med | FMI | 7/5/16 | 20.4 | 34 | 68 | 40.2 | 127.12 | |
Gilead Sci | GILD | 2/3/16 | 85.8 | 67.3 | -20.9 | 81.02 | 15.29 | |
Roche ADR | RHHBY | 4/4/16 | 30.36 | 32.4 | 7.9 | 32 | 12.16 | |
IBB | 6/29/16 | 250 | 296 | 18.4 | 33.59 | 25.7 | ||
XBI | 1/31/17 | 64 | 70.7 | 9.4 | 86.57 | 46.26 | ||
QQQ (reference) | n/a | 135.13 | n/a | 145.45 | 22.76 | |||
FBIOX (reference)
|
n/a | 232.77 | 33.74 | |||||